



HAL
open science

The Hellenic type of nondeletional hereditary persistence of fetal hemoglobin results from a novel mutation (g.-109G>T) in the gene promoter

Christos Chassanidis, Angelos Kalamaras, Marios Phylactides, Farzin Pourfarzad, Sophia Likousi, Vassilis Maroulis, Manoussos N. Papadakis, Nikolaos K. Vamvakopoulos, Vassiliki Aleporou-Marinou, George P. Patrinos, et al.

► To cite this version:

Christos Chassanidis, Angelos Kalamaras, Marios Phylactides, Farzin Pourfarzad, Sophia Likousi, et al.. The Hellenic type of nondeletional hereditary persistence of fetal hemoglobin results from a novel mutation (g.-109G>T) in the gene promoter. *Annals of Hematology*, 2008, 88 (6), pp.549-555. 10.1007/s00277-008-0643-0 . hal-00535006

HAL Id: hal-00535006

<https://hal.science/hal-00535006>

Submitted on 11 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

The Hellenic type of nondeletional hereditary persistence of fetal hemoglobin results from a novel mutation (g.-109G>T) in the *HBG2* gene promoter

Christos Chassanidis · Angelos Kalamaras ·
Marios Phylactides · Farzin Pourfarzad ·
Sophia Likousi · Vassilis Maroulis ·
Manoussos N. Papadakis ·
Nikolaos K. Vamvakopoulos ·
Vassiliki Aleporou-Marinou · George P. Patrinos ·
Panagoula Kollia

Received: 15 May 2008 / Accepted: 10 November 2008 / Published online: 3 December 2008
© Springer-Verlag 2008

Abstract Nondeletional hereditary persistence of fetal hemoglobin (nd-HPFH), a rare hereditary condition resulting in elevated levels of fetal hemoglobin (Hb F) in adults, is associated with promoter mutations in the human fetal globin (*HBG1* and *HBG2*) genes. In this paper, we report a novel type of nd-HPFH due to a *HBG2* gene promoter mutation (*HBG2*:g.-109G>T). This mutation, located at the 3' end of the *HBG2* distal CCAAT box, was initially identified in an adult female subject of Central Greek origin and results in elevated Hb F levels (4.1%) and significantly increased G γ -globin chain production (79.2%). Family studies and DNA analysis revealed that the *HBG2*:g.-109G>T mutation is also

found in the family members in compound heterozygosity with the *HBG2*:g.-158C>T single nucleotide polymorphism or the silent *HBB*:g.-101C>T β -thalassemia mutation, resulting in the latter case in significantly elevated Hb F levels (14.3%). Electrophoretic mobility shift analysis revealed that the *HBG2*:g.-109G>T mutation abolishes a transcription factor binding site, consistent with previous observations using DNA footprinting analysis, suggesting that guanine at position *HBG2/1*:g.-109 is critical for NF-E3 binding. These data suggest that the *HBG2*:g.-109G>T mutation has a functional role in increasing *HBG2* transcription and is responsible for the HPFH phenotype observed in our index cases.

Marios Phylactides and Farzin Pourfarzad contributed equally to this work.

C. Chassanidis · A. Kalamaras · S. Likousi ·
N. K. Vamvakopoulos · P. Kollia
Department of Biology, School of Medicine,
University of Thessaly,
Larissa, Greece

A. Kalamaras
Prevention Center of Thalassemia,
General Hospital of Karditsa,
Karditsa, Greece

M. Phylactides
Cyprus Institute of Neurology and Genetics,
Nicosia, Cyprus

F. Pourfarzad · G. P. Patrinos (✉)
MGC-Department of Cell Biology and Genetics,
Faculty of Medicine and Health Sciences, Erasmus MC,
Rotterdam, The Netherlands
e-mail: g.patrinos@erasmusmc.nl

V. Maroulis · V. Aleporou-Marinou · P. Kollia (✉)
Department of Genetics and Biotechnology, Faculty of Biology,
School of Physical Sciences, National and Kapodistrian
University of Athens,
Panepistimioupolis,
157 01 Athens, Greece
e-mail: pankollia@biol.uoa.gr

M. N. Papadakis
Center for Thalassemia, Unit of Prenatal Diagnosis,
LAIKO General Hospital,
Athens, Greece

Keywords Nondeletional hereditary persistence of fetal hemoglobin · β -thalassemia · Fetal globin genes · *HBG2* · Mutation · Regulatory element · Transcription

Introduction

Hereditary persistence of fetal hemoglobin (HPFH) is a genetic condition characterized by persistent elevated levels of fetal hemoglobin (Hb F) in the adult erythroid stage [1]. HPFH heterozygotes have a normal clinical phenotype and hematological indices, except for the lower levels of hemoglobin A₂ (Hb A₂) that constitutes the hallmark of HPFH. The reason for that is the increased frequency of interactions between the locus control region (LCR) and the mutated γ -globin gene promoter compared to the normal situation. Subsequently, this shifts the transcriptional balance in favor to the otherwise silent, fetal globin genes, resulting in lower *HBD* gene transcription and Hb A₂ levels [2].

The various forms of HPFH are distinguished into two main categories, namely, deletional and nondeletional HPFH (nd-HPFH), due to large deletions 3' to the fetal globin genes or nucleotide substitutions in the fetal globin gene promoters, respectively [3]. The current explanation for the functional role of the latter HPFH category is the destabilization of a yet unknown silencing protein complex that permits LCR–gene interactions and recruitment of the basal transcriptional machinery to the mutated γ -globin gene promoter, leading to reactivation of fetal globin gene transcription [4].

To date, there are few γ -globin promoter mutations, leading to nd-HPFH clustered on or in close proximity to γ -globin gene *cis*-regulatory elements [5]. The most important nd-HPFH is the Greek type (*HBG1*:g.-117G>A [6]), whose functional role is also demonstrated in transgenic mice [7]. This mutation is located at the 5' end of the distal γ -globin gene CCAAT box where important erythroid-specific transcription factors bind. Other mutations cluster approximately 200 bp upstream to the γ -globin genes transcription initiation site where a GC-rich region is located. Although clinically silent, the mutations leading to nd-HPFH provide valuable insights into the transcriptional regulation of the human fetal globin genes, which in turn can enable design of novel strategies for β -thalassemia therapeutics.

In this communication, we report the Hellenic type of nd-HPFH due to a novel G>T transversion in the *HBG2* gene promoter, located at the 3' end of the distal *HBG2* CCAAT box.

Materials and methods

Case selection

For the needs of this study, the mother and two sisters of the index case were also recruited. Unfortunately, the father

of the index case was deceased, but, nevertheless, his sister was available for study (Fig. 1a). Also, 31 heterozygotes for the silent *HBB*:g.-101C>T β -thalassemia mutation have been included (Table 1), as well as 89 normal (non-thalassemic) individuals. The study was previously approved by the hospital's ethics committee.

Hemoglobin studies

Blood samples were collected, with consent, in vacutainers with ethylenediaminetetraacetic acid as anticoagulant. Hematological indices were measured with an automated cell counter and Hb A₂ and Hb F levels were quantitated, using cation exchange high-performance liquid chromatography (HPLC; VARIANT™, BioRad, Hercules, CA, USA). Globin chain quantitation was performed using reverse-phase HPLC, using the RP-18 column (Pharmacia, Uppsala, Sweden).

DNA analysis

Total genomic DNA isolation and γ -globin gene promoters' amplification was done as previously described [8]. Mutation screening in the human γ -globin gene promoters was performed using denaturing gradient gel electrophoresis (DGGE) with a 40–70% linear gradient of denaturing agents (urea and formamide; 100% denaturant: 7 M urea, 40% formamide), as previously described [9]. *HBB* and *HBD* gene mutation screening was done as described in Losekoot and coworkers [10] and Papadakis and coworkers [11], respectively. Automated DNA sequencing was performed directly on the polymerase chain reaction (PCR) products. Screening for *HBA2/1* gene deletions was done according to the multiplex gap-PCR strategy of Tan and coworkers [12], while a PCR-restriction fragment length polymorphism (RFLP) approach was used to screen for the commonest point mutations and small indels in the *HBA2/1* genes, leading to nondeletional α -thalassemia in the Hellenic population [13].

Electrophoretic mobility shift assays

Electrophoretic mobility shift assays (EMSA) analysis was performed using total nuclear protein extracts from mouse erythroleukemia (MEL) and human K562 cells [14]. In brief, 5 μ g nuclear extracts were used per reaction and competitions were done using 100-fold molar excess of the indicated double-stranded oligonucleotides before addition of the nuclear extract. Nucleotide sequence of the oligonucleotides used in these studies is available upon request. Supershift analysis was performed using a home-brewed GATA-1 antibody [15, 16].

Fig. 1 a Family tree showing the heterozygous and compound heterozygous cases for the Hellenic type of nd-HPFH, bearing the novel *HBG2:g.-109G>T* promoter mutation (depicted in *black*) and the *HBG2:g.-158C>T* polymorphism (depicted in *light gray*) or the silent *HBB:g.-101C>T* β -thalassemia nonsense mutation (depicted in *dark gray*), along with the corresponding hematological indices. **b** Chromatogram from RP-HPLC from the index case showing the significant increase in the $\text{G}\gamma/\text{A}\gamma$ -globin chain ratio




Table 1 Comparison of the hematological indices, Hb A₂ and Hb F levels among the compound heterozygous for the novel *HBG2:g.-109G>T* mutation and the silent *HBB:g.-101C>T* β -thalassemia

mutation (I-3; see also Fig. 1a), and heterozygotes for the silent *HBB:g.-101C>T* β -thalassemia mutation (note the markedly increased Hb F levels in case I-3)

Hematological indices	<i>HBB:g.-101C>T</i>		
	<i>HBG2:g.-109G>T</i> (I-3)	Wild-type Females (n=18)	Wild-type Males (n=13)
Age (years)/sex	78/F	Adults	Adults
Hb (g/dL)	12.1	12.4±1.22	14.5±0.84
Hct (%)	38.5	37.1±2.76	43.1±2.30
RBC (×10 ⁶)	4,440	4,382±446	5,144±265
MCH (pg)	27.3	28.4±1.54	28.5±0.88
MCV (fl)	86.7	85.5±4.03	84.3±2.69
MCHC (%)	31.4	32.7±1.04	33.9±0.64
Hb A ₂ (%)	4.3	3.79±0.24	3.92±0.37
Hb F (%)	14.3	2.53±1.8	1.60±1.17

Results

During routine carrier screening for β -thalassemia, an adult female subject was identified with moderately elevated Hb F levels (4.1%) and significantly increased G γ /A γ -globin chain ratio (Fig. 1b). An aberrant electrophoretic pattern was identified during mutation screening in the *HBG2* promoter by DGGE analysis (Fig. 2a). DNA sequencing of the proximal *HBG2* promoter region revealed a novel sequence variation, namely, a G>T transversion at position -109 relative to the gene's transcription initiation site (*HBG2*:g.-109G>T; Fig. 2b). DNA sequencing did not reveal any other variant nucleotide in either one of the γ -globin genes promoters and distal 5' regulatory regions between positions -672 and +25. Neither the *HBG2*:g.-158C>T (XmnI) nor the *HBG1*:g.-225-222(AGCA)del polymorphisms, which are often correlated with moderately increased HbF levels, were found in the index case.

Hemoglobin studies and DNA analysis of the available family members indicated that the propositus mother (I-2) was a carrier of the *HBG2*:g.-158C>T (XmnI) polymorphism, while both sisters (II-2, II-3) were compound heterozygotes for the *HBG2*:g.-158C>T polymorphism and the novel *HBG2*:g.-109G>T mutation. Surprisingly, in the latter cases, Hb F levels were normal. Although the propositus father was deceased, his sister, who was available for study, presented with significantly increased Hb F levels (14.3%; Table 1, Fig. 1a). DNA analysis revealed that the propositus aunt (I-3) was also compound heterozygous for the *HBG2*:g.-109G>T promoter mutation and the silent *HBB*:g.-101C>T β -thalassemia mutation. The *HBG2*:g.-109G>T base substitution was neither identified in 31 β -thalassemic chromosomes, bearing the silent *HBB*:g.-101C>T mutation nor in 209 normal (nonthalassemic) chromosomes, suggesting that the novel *HBG2*:g.-109G>T variation is not a frequent polymorphism. Mutation screening in the *HBD* gene in the index case and her family members, using DGGE analysis [11], failed to identify any *HBD* mutations (data not shown). In addition, all family members were not carriers either of known *HBA2/1* gene deletions or the commonest point mutations and small indels in the *HBA2/1* genes, determined by gap-PCR and PCR-RFLP analysis, respectively.

In order to verify the functional significance of the novel *HBG2*:g.-109G>T mutation, we measured G γ -globin chain levels, using reverse-phase HPLC. Our results showed that the G γ /A γ -globin chain ratio was significantly increased, compared to normal (nonthalassemic) individuals and carriers for the *HBB*:g.-101C>T mutation (79.2/20.8 versus 40/60, respectively) [17]. Also, we performed EMSA analysis, using nuclear extracts from both MEL cells and human K562 cells, expressing the adult and fetal erythroid program, respectively, in order to assess whether the




Fig. 2 **a** DGGE analysis of the promoter region of the *HBG2* gene. Numbering correlates with the family tree in Fig. 1a. Note the mutant *HBG2*:g.-158 T (lower band) and *HBG2*:g.-109 T homoduplexes (upper band) that comigrate in lanes II-2 and II-3, compared to lanes I-2 and II-1, respectively. The 40–70% denaturing gradient corresponds to the top and bottom of the gel, respectively. **b** DNA sequencing analysis, performed in the forward and reverse (not shown) orientation, revealing a G>T transition at position -109 of the *HBG2* gene promoter (arrow)

HBG2:g.-109G>T mutation affects protein binding in vitro. Indeed, EMSA analysis using a 40-bp oligonucleotide bearing the wild-type sequence (G) at position *HBG2*:g.-109 showed a double-band electrophoretic pattern, suggesting that two proteins and/or protein complexes bind to the oligonucleotide used. Addition of nonradioactive GATA-1 oligonucleotides, both from *HBG2* and *HBB* promoters [15], resulted only in the lower band being efficiently competed, contrary to the upper band that remained visible (Fig. 3a), indicating that the lower band most likely




Fig. 3 a Electrophoretic mobility shift assays of the oligonucleotides containing either the wild-type (*Wt*; *HBG2*:g-109 G) or mutant (*Mt*; *HBG2*:g-109 T) sequence using nuclear protein extracts prepared from dimethyl sulfoxide-induced MEL cells. The *HBG2* -109Mt oligonucleotide most likely abolishes a NF-E3 binding site in vitro (depicted as two asterisks). Competition with nonlabeled *HBG2* -109Wt oligonucleotide results in the disappearance of GATA-1 and NF-E3 band shifts, suggesting that both proteins bind to the *HBG2* -109Wt oligonucleotide. Competition with nonlabeled *HBG2* -567 or *HBB* GATA-1 oligonucleotides [15] results in the disappearance only of the GATA-1 (lower) band. Competition with nonlabeled *HBG2* -567 or *HBB* GATA-1 oligonucleotides suggests that the affinity of GATA-1 is

stronger to the former oligonucleotide. Use of nuclear protein extracts prepared from K562 cells yielded identical electrophoretic mobility shifts (not shown). The asterisk indicates the oligonucleotide sequence located in the *HBB* gene promoter region. **b** Schematic representation of the various nd-HPFH mutations reported to date for the *HBG2* (in red) and *HBG1* (in blue) globin genes (underlined sequences depict the two small deletions also leading to nd-HPFH). The novel nd-HPFH mutation reported in this study is highlighted in red. Gray box represents the sequences downstream to the transcription initiation site and sequences in solid black boxes represent phylogenetically conserved fetal globin genes *cis*-regulatory elements

represents GATA-1 binding. This finding was confirmed using GATA-1 antibody, resulting in a supershift of the lower (GATA-1) band (data not shown). EMSA analysis using a 40-bp oligonucleotide bearing the mutant sequence (T) at position *HBG2*:g.-109 revealed that binding of the protein (or protein complex) in the upper band was abolished. These data indicate that the upper band shift represent protein (or protein complex) binding only to the wild-type sequence at position *HBG2*:g.-109 (G) and that the *HBG2*:g.-109G>T transversion inhibits protein binding in vitro. Consistent with previous footprinting experiments [18], these data suggest that the *HBG2*:g.-109G>T mutation is responsible for the resulting nd-HPFH phenotype.

Discussion

In this paper, we report the Hellenic type of nd-HPFH, resulting from a novel G>T transversion in the promoter region of the *HBG2* gene. In the Hellenic population, the dominant nd-HPFH is the Greek type (*HBG1*:g.-117G>A [6]), accounting for almost 90% of the HPFH chromosomes [9]. The Cretan nd-HPFH (*HBG1*:g.-158C>T [9]) is the second most frequent type, followed by the *HBG1*:g.-201C>T and the *HBG2*:g.-196C>T mutations [19]. No deletional HPFH has even been reported for the Hellenic population.

The *HBG2*:g.-109G>T mutation was found both in heterozygosity as well as in compound heterozygosity with

the *HBG2*:g.-158C>T (XmnI) polymorphism and the silent *HBB*:g.-101C>T β -thalassemia mutation, the latter being one of the most common *HBB* mutation leading to β -thalassemia in the Hellenic population [20, 21]. Interestingly, however, the resulting Hb F levels varied in each case. First of all, heterozygosity for the *HBG2*:g.-109G>T mutation resulted in moderately increased Hb F levels in the index case (4.1%). Also, compound heterozygosity with the silent *HBB*:g.-101C>T β -thalassemia mutation resulted in substantially increased Hb F levels (14.3%), as expected for compound heterozygous cases for nd-HPFH and β -thalassemia [22]. There are very few examples of nd-HPFH/ β -thalassemia compound heterozygous cases, which are extremely rare and only occasionally reported in the literature [22, 23]. On the contrary, compound heterozygosity for the *HBG2*:g.-109G>T mutation and the *HBG2*:g.-158C>T polymorphism has no effect in the observed Hb F levels (Fig. 1a). There are two possible explanations for this observation: (a) the *HBG2*:g.-158C>T polymorphism itself exerts a silencing effect on the *HBG2*:g.-109G>T mutation or (b) another yet unidentified *cis*-regulatory element suppresses Hb F production in the sisters of the index case. The latter assumption resembles our recent findings [16] and reaffirms that the regulation of γ -globin gene expression and Hb F production is multifactorial and likely combinatorial and that many genetic factors can putatively impact Hb F production in adults.

The *HBG2*:g.-109G>T mutation resides at the 3' end of the distal *HBG2* CCAAT box where the CP1 and NF-E3 transcription factors bind [18]. On the basis of in vitro binding studies, GATA-1 and NF-E3 have both been implicated as candidate suppressors of γ -globin gene transcription that would act by binding to the region [18, 24]. In particular, guanosine at position *HBG2*:g.-109 has been previously shown to be a strong contact point for NF-E3 [24], suggesting that the *HBG2*:g.-109G>T transversion activates Hb F production most likely by abolishing NF-E3 binding. This assumption is in accordance with our EMSA analysis data indicating that the *HBG2*:g.-109G>T transversion results in abolishing protein binding in vitro (Fig. 3a). Taking into consideration that the γ -globin chain levels were doubled in the index case (I-1; Fig. 1a), these data strongly suggest that the *HBG2*:g.-109G>T mutation is responsible for the resulting HPFH phenotype.

The novel nd-HPFH mutation described in this paper is located at the 3' end of the *HBG2* gene's distal CCAAT box, a phylogenetically conserved *cis*-regulatory element that has been shown to harbor many ubiquitous and erythroid-specific transcription factor binding sites [1]. Nine out of 21 nd-HPFH mutations have been identified in this region (Fig. 3b), suggesting that this regulatory element is critical for γ -globin gene transcription. Contrary, however, to the majority of these nd-HPFH mutations that

have a substantial effect in Hb F production, the *HBG2*:g.-109G>T nd-HPFH mutation per se results in only moderate increase in HbF levels. In addition, the neighboring *HBG2*:g.-110A>C mutation, leading to the Czech nd-HPFH, also has a negligible effect in HbF production [25]. This is unexpected since the *HBG1*:g.-117G>A nd-HPFH mutation, residing at the 5' end of the distal CCAAT box, leads to a substantial increase in γ -globin gene transcription. This can be explained by the fact that (a) different mutations in the distal CCAAT box abolish different transcription factors binding [24], which would exert a differential effect over γ -globin gene reactivation in the adult stage, (b) the *HBG1*:g.-117G>A and *HBG2*:g.-109G>T reside on different genes, hence their relative distance from the LCR, being directly proportional to the frequency of LCR/globin gene promoter interactions [26], varies. It is noteworthy that not all nd-HPFH mutations give a reproducible HPFH phenotype in transgenic mice (unpublished data).

Altogether, these data emphasize that γ -globin gene silencing should be the result of a gradual change in the transcription factor environment affecting the transcriptional balance between the *HBG1*/*HBG2* and *HBB* genes.

Acknowledgements This work was partly supported by grants from the Greek Ministry of Education (Pythagoras 52211.08) to PK and the Research Promotion Foundation (Cyprus, ΠΔΕ046_02) and the European Commission [International Thalassemia Network (ITHANET) Coordination action 026539] to GPP.

References

1. Stamatoyannopoulos G, Grosveld F (2001) Hemoglobin switching. In: Stamatoyannopoulos G, Majerus P, Perlmutter R, Varmus H (eds) Molecular basis of blood diseases, 3rd edn. Saunders, Philadelphia, pp 135–182
2. Wijgerde M, Grosveld F, Fraser P (1995) Transcription complex stability and chromatin dynamics in vivo. *Nature* 377:209–213, doi:10.1038/377209a0
3. Bollekens JA, Forget BG (1991) Deltabeta thalassemia and hereditary persistence of fetal hemoglobin. *Hematol Oncol Clin North Am* 5:399–422
4. Swank RA, Stamatoyannopoulos G (1998) Fetal gene reactivation. *Curr Opin Genet Dev* 8:366–370, doi:10.1016/S0959-437X(98)80095-6
5. Hardison RC, Chui DH, Giardine B, Reimer C, Patrinos GP, Anagnou N, Miller W, Wajcman H (2002) HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. *Hum Mutat* 19:225–233, doi:10.1002/humu.10044
6. Gelinas R, Endlich B, Pfeiffer C, Yagi M, Stamatoyannopoulos G (1985) G to A substitution in the distal CCAAT box of the A gamma-globin gene in Greek hereditary persistence of fetal haemoglobin. *Nature* 313:323–325, doi:10.1038/313323a0
7. Berry M, Grosveld F, Dillon N (1992) A single point mutation is the cause of the Greek form of hereditary persistence of fetal haemoglobin. *Nature* 358:499–502, doi:10.1038/358499a0
8. Patrinos GP, Loutradi-Anagnostou A, Papadakis MN (1995) A novel DNA polymorphism of the Agamma globin gene

- (Agamma-588 A>G) is linked with the XmnI polymorphism (Ggamma-158 C>T). Hemoglobin 19:419–423, doi:10.3109/03630269509005835
9. Patrinos GP, Kollia P, Loutradi-Anagnostou A, Loukopoulos D, Papadakis MN (1998) The Cretan type of non-deletional hereditary persistence of fetal hemoglobin [Agamma-158 C>T] results from two independent gene conversion events. Hum Genet 102:629–634, doi:10.1007/s004390050753
 10. Losekoot M, Fodde R, Hartveld CL, van Heeren H, Giordano PC, Bernini LF (1990) Denaturing gradient gel electrophoresis and direct sequencing of PCR amplified genomic DNA: a rapid and reliable diagnostic approach to beta thalassemia. Br J Haematol 76:269–274, doi:10.1111/j.1365-2141.1990.tb07883.x
 11. Papadakis MN, Papapanagiotou E, Loutradi-Anagnostou A (1997) Scanning method to identify the molecular heterogeneity of the delta-globin gene, especially in delta-thalassemias: detection of three novel mutations in the promoter region of the gene. Hum Mutat 9:465–472, doi:10.1002/(SICI)1098-1004(1997)9:5<465::AID-HUMU14>3.0.CO;2-0
 12. Tan AS, Quah TC, Low PS, Chong SS (2001) A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for alpha-thalassemia. Blood 98:250–251, doi:10.1182/blood.V98.1.250
 13. Patrinos GP, van Baal S, Petersen MB, Papadakis MN (2005) Hellenic National Mutation database: a prototype database for mutations leading to inherited disorders in the Hellenic population. Hum Mutat 25:327–333, doi:10.1002/humu.20157
 14. Papachatzopoulou A, Kaimakis P, Pourfarzad F, Menounos PG, Evangelakou P, Kollia P, Grosveld FG, Patrinos GP (2007) Increased gamma-globin gene expression in beta-thalassemia intermedia patients correlates with a mutation in 3'HS1. Am J Hematol 82:1005–1009, doi:10.1002/ajh.20979
 15. Luo HY, Mang D, Patrinos GP, Pourfarzad F, Wuc CJY, Eung SH, Rosenfield CG, Daoust PR, Braun A, Grosveld FG, Steinberg MH, Chui DHK (2004) A novel single nucleotide polymorphism (SNP), T>G, in the GATA site at nucleotide (nt) –567 5' to the Ggamma-globin gene may be associated with elevated Hb F. Blood 104:145a–146a
 16. Chen Z, Luo HY, Basran RK, Hsu TH, Mang DW, Nuntakarn L, Rosenfield CG, Patrinos GP, Hardison RC, Steinberg MH, Chui DH (2008) A T-to-G transversion at nucleotide –567 upstream of HBG2 in a GATA-1 binding motif is associated with elevated hemoglobin F. Mol Cell Biol 28:4386–4393, doi:10.1128/MCB.00071-08
 17. Huisman TH, Harris H, Gravely M, Schroeder WA, Shelton JR, Shelton JB, Evans L (1977) The chemical heterogeneity of fetal hemoglobin in normal newborn infants and in adults. Mol Cell Biochem 17:45–55, doi:10.1007/BF01732554
 18. Ronchi AE, Bottardi S, Mazzucchelli C, Ottolenghi S, Santoro C (1995) Differential binding of the NFE3 and CP1/NFY transcription factors to the human gamma- and epsilon-globin CCAAT boxes. J Biol Chem 270:21934–21941, doi:10.1074/jbc.270.37.21934
 19. Tasiopoulou M, Boussiou M, Sinopoulou K, Moraitis G, Loutradi-Anagnostou A, Karababa P (2008) (G)gamma-196 C->T, (A) gamma-201 C->T: two novel mutations in the promoter region of the gamma-globin genes associated with nondeletional hereditary persistence of fetal hemoglobin in Greece. Blood Cells Mol Dis 40:320–322, doi:10.1016/j.bcmd.2007.10.007
 20. Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou NP, Wajcman H, Hardison RC (2004) Improvements in the *HbVar* human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res 32:D537–D541, doi:10.1093/nar/gkh006
 21. van Baal S, Kaimakis P, Phommarnin M, Koumbi D, Cuppens H, Riccardino F, Macek M Jr, Scriver CR, Patrinos GP (2007) FINDbase: a relational database recording frequencies of genetic defects leading to inherited disorders worldwide. Nucleic Acids Res 35:D690–D695, doi:10.1093/nar/gkl934
 22. Papadakis MN, Patrinos GP, Tsaftaris P, Loutradi-Anagnostou A (2002) A comparative study of Greek non-deletional hereditary persistence of fetal hemoglobin and beta-thalassemia compound heterozygotes. J Mol Med 80:243–247, doi:10.1007/s00109-001-0312-4
 23. Kollia P, Kalamaras A, Chassanidis C, Samara M, Vamvakopoulos NK, Radmilovic M, Pavlovic S, Papadakis MN, Patrinos GP (2008) Compound heterozygosity for the Cretan type of non-deletional hereditary persistence of fetal hemoglobin and beta-thalassemia or Hb Sabine confirms the functional role of the Agamma-158 C>T mutation in gamma-globin gene transcription. Blood Cells Mol Dis 41:263–264
 24. Ronchi A, Berry M, Raguz S, Imam A, Yannoutsos N, Ottolenghi S, Grosveld F, Dillon N (1996) Role of the duplicated CCAAT box region in gamma-globin gene regulation and hereditary persistence of fetal haemoglobin. EMBO J 15:143–149
 25. Indrak K, Indrakova J, Kutlar F, Pospisilova D, Sulovska I, Baysal E, Huisman THJ (1991) Compound heterozygosity for a beta0-thalassemia (frameshift codons 38/39; –C) and a nondeletional Swiss type of HPFH (A>C) at NT –110, Ggamma) in a Czechoslovakian family. Ann Hematol 63:111–115, doi:10.1007/BF01707283
 26. Patrinos GP, de Krom M, de Boer E, Langeveld A, Imam AM, Strouboulis J, de Laat W, Grosveld FG (2004) Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes Dev 18:1495–1509, doi:10.1101/gad.289704